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Disclaimer: Due to the rapidly evolving nature of this 
outbreak, and in the interests of rapid dissemination of 
reliable, actionable information, this paper went through 
expedited peer review. Additionally, information should be 
considered current only at the time of publication and may 
evolve as the science develops.
 
As an emergency and wellness physician, scientist, father, 
and 55-year-old man, I have a keen interest in the coronavirus 
and the resulting COVID-19/severe acute respiratory 
syndrome (SARS) CoV2 illness. Based on all I have heard 
from the scientific community, a review of the literature, 
and a review of historical facts related to other epidemics, 
I believe we are missing some key points, particularly with 
regard to how we are approaching prevention of morbidity 
and mortality. My opinion is the virus is not killing people, 
but rather the immune response to the virus. Perhaps we need 
to shift our thinking from screening and treating signs and 
symptoms to add risk stratifying, measuring, and treating 
inflammation. I think this approach needs to be seriously 
vetted. It might be used to screen not just our patients, but 
also our physicians and nurses to determine who should be 
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seeing patients frontline vs remotely, which patients should be 
admitted, and which should be sent home. 
In the 1918 influenza pandemic, roughly 25% of the 
world’s population was infected and it caused between 50 
million and 100 million deaths.1 If we want to have a different 
outcome, we have to do something different. I agree that 
social distancing and quarantine are both key measures to 
flatten the curve (Figure 1) and slow transmission so that 
resources are not as overwhelmed. However, we must also 
consider novel approaches to treat patients who have been 
infected or may get infected while we wait for a vaccine. 
To manage these patients appropriately we must examine 
the cause of the morbidity and mortality associated with 
COVID-19. Historically, we know viral infections mostly 
affect young children and the elderly. This is primarily due 
to these populations being very susceptible to dehydration. 
However, this novel virus largely spares the young and preys 
primarily on those over 40. 
This graph in Figure 2 shows the age of those discharged 
vs died from the first 150 cases in Wuhan, China.2 From 
the initial Chinese data, there were no deaths under age 40 
with the first 150 patients. The Chinese Center for Disease 
Figure 1. Using protective measures such as social distancing slows virus transmission and eases pressure on hospitals and providers.
Adapted from the CDC/The Economist. Available at: https://www.nytimes.com/article/flatten-curve-coronavirus.html.
# 
of
 c
as
es
Time since first case
Western Journal of Emergency Medicine 474 Volume 21, no. 3: May 2020
Paradigm Shift for COVID-19 Response Kivela
Control data show the mortality rate logarithmically 
increased as patients reach 40 years of age3 (Table 1). 
Preliminary US and Italian data are similar with even more 
emphasis on older patients.4
Symptoms for younger people are generally mild and 
many are even asymptomatic. Figure 3 illustrates that the 
cause of death is from organ failure, usually the lungs or heart.2 
Therefore, we must look beyond complications of dehydration 
as a key factor and look at the body’s immune response to this 
novel virus instead. 
The immune response to this virus seems to be largely 
consistent with cytokine release syndrome (CRS/cytokine 
storm). CRS/cytokine storm is a severe systemic inflammatory 
response that can arise from multiple conditions including 
infectious and non-infectious diseases, including graft vs host 
disease, Ebola virus disease, smallpox, and even infusion 
reactions from certain medications. It is postulated that CRS/
cytokine storm was the primary cause of mortality in the 1918 
influenza pandemic, SARS, H5N1, and hantavirus outbreaks. 
Signs and symptoms of CRS/cytokine storm are the same 
symptoms that critical COVID-19 patients are presenting 
with including fever, rapid respirations and heartrate, cough, 
shortness of breath, fatigue, loss of appetite, muscle and joint 
pain, nausea, vomiting, diarrhea, low blood pressure, seizures, 
headache, confusion, and delirium. We must go beyond 
treating this illness with supportive measures and also treat 
the inflammatory response to the virus. We have to shift our 
thinking as many physicians and healthcare workers are not 
familiar with CRS/cytokine storm.
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Figure 2. Age of discharged patients vs those who died among 
the first 150 cases of COVID-19 in China.2
Age Group Mortality rate
80+ years old 14.8%
70-79 years old 8.0%
60-69 years old 3.6%
50-59 years old 1.3%
40-49 years old 0.4%
30-39 years old 0.2%
20-29 years old 0.2%
10-19 years old 0.2%
0-9 years old None
Table 1. COVID-19 mortality rate by age.
What we know about seriously ill COVID-19 patients is 
that they develop a lymphopenia (low T-cell count) and bilateral 
pulmonary infiltrates, which is likely acute respiratory distress 
syndrome (ARDS/respiratory failure) and/or heart failure. Many 
critical patients have elevated cardiac enzymes, inflammatory 
markers (C-reactive protein [CRP]), and an elevated 
interleukin-6 (IL-6) level (Figure 4).2 Testing patients for the 
virus is probably not enough. Furthermore, we should also 
consider using other screening tools that measure inflammation 
such as CRP, IL-6, and ferritin levels5 so that we can identify 
those patients who are at higher risk of decompensating.
CRS/cytokine storm occurs when white blood cells 
are activated and release inflammatory signals (cytokines) 
that further activate more white blood cells. One of the key 
cytokines is IL-6, which is also involved in rheumatoid 
arthritis and several cancers. Traditionally, care for CRS has 
been supportive, addressing the symptoms of fever, oxygen, 
Figure 3. In COVID-19 patients the cause of death is primarily 
from organ failure, usually the lungs or heart.2
Respiratory Failure
Respiratory Failure with Myocardial Damage/Heart Failure
Myocardial Damage/Heart Failure
Unknown
36 (53%)
22 (33%)
5 (7%)
5 (7%)
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fluids, and medications to raise blood pressure. Traditionally, 
we have used nonsteroidal anti-inflammatory drugs and 
corticosteroids to treat severe CRS in people with ARDS; 
however, they have not been shown to have any significant 
effect on outcomes. Some human immunodeficiency virus 
medications may be promising but similarly have not yet been 
proven to be effective. 
Biologics are likely the most useful medications in our 
arsenal to treat CRS/cytokine storm, as they have been shown 
to improve the immune response by decreasing IL-6. There 
are two biologic medications approved by the US Food and 
Drug Administration for anti-IL-6 therapy that may be useful 
for treating critical COVID-19 patients. Those medications 
include tocilizumab (Actemra), an antibody directed against 
the IL-6 receptor, and siltuximab (Sylvant), which is an anti-
IL-6 chimeric monoclonal antibody. ACE inhibitors and ARB 
(angiotensin II receptor blockers) have also been shown to 
decrease IL-6 levels.6
Recent reports indicate that the US is studying 
azithromycin7 and hydroxychloroquine.8 Both of these 
medications have been found to decrease IL-6 levels. Some of 
these medications are being investigated and used in China,9 
but as a healthcare worker in the US I have not heard that of 
many who are considering using medications. 
We should also take notice that this virus is 
disproportionately affecting older men and post-menopausal 
women. It is interesting that testosterone levels decrease after 
age 30 in men (and after menopause for women). Patients with 
low testosterone have elevated IL-6 levels, higher incidences 
of diabetes, high rates of obesity, and higher overall mortality. 
The Journal of the American Geriatric Society found that “older 
age, adiposity, slower walking speed, higher disease burden and 
white blood cell count were associated with increased risk of 
IL-6 elevation over a three-year period.”10 A study published in 
the journal Clinical Endocrinology and Metabolism concluded 
that “testosterone replacement shifts the cytokine balance to a 
state of reduced inflammation” and decreases IL-6.11
There is a long list of other substances and behaviors that 
can also potentially decrease IL-6 including the following12: 
Vitamin D3,13 zinc,14 magnesium,15, probiotics,16 aspirin,17 
fish oil/DHA,18 and resveratrol,19 to name a few. Conversely, 
diabetes, high blood sugar, high glycemic load foods, starchy 
foods, and potentially coffee can actually increase IL-6 levels. 
So what can we do? I recommend that the public 
continue to adhere to recommendations set forth by 
government health officials, but go one step further and take 
steps to decrease inflammation by limiting sugary and fatty 
foods, exercising daily (preferably outdoors) and consider 
taking appropriate supplements to decrease IL-6 levels, and 
consider testosterone therapy especially in those individuals 
with low hormone levels.
I also recommend that physicians and healthcare 
providers continue to use supportive measures, but also 
consider screening by measuring inflammatory markers, risk-
Figure 4. Inflammatory markers are indicative of higher mortality.2
Died
Discharged
Cardiac Troponin
(pg/mL)
Myoglobin
(ng/mL)
C-reactive Protein
(mg/L)
Interleukin-6
(pg/mL)
P < 0.001 P < 0.001 P < 0.001 P < 0.001
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categorizing individuals, treating the immune response to 
this virus, and studying anti-inflammatory therapies. We can 
also possibly use inflammatory markers to help risk-stratify 
which providers should be working on the frontline and 
which should work remotely. We cannot sit by idly waiting 
for a vaccine and simply use supportive measures as we get 
overwhelmed with patients. We must be brave and consider 
novel approaches to identify, triage, and manage patients 
affected by this novel virus.
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